TP53 and malignant colon neoplasm: We found that inhibition of ATGL abrogated critical drivers of colon cancer progression including RARA, MYC, ERBB2, AREG, and FOXM1, while promoting those with tumor-suppressive function such as FOXO3, TP53, and CDKN1A (Fig. 4E, IPA).